Critical Pharmaceuticals
HomeCompany ProfileNewsTechnologyManagement TeamPipelineEventsContact Us

Latest News

6th September 2011
  Interim Results of CP024 Nasal hGH Phase 1 Program Show Comparable Bioactivity to Injection
5th April 2011
  PolyTherics and Critical Pharmaceuticals enter drug development collaboration with TSB funding
8th March 2011
  CriticalSorb Delivery Technology Shows Excellent Local Tolerability in Long Term Preclinical Studies
Technology
 

Technology

Critical Pharmaceuticals has developed two unique drug delivery technologies:

CriticalSorb for the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.

CriticalMix for the manufacture of highly active sustained release depot products for bimonthly, monthly or even less frequent injection.

 

 
 

 

Videos

The movie on the right shows CO2 reaching and passing through its critical point (31°C / 74bar). Notice as the CO2 becomes supercritical the meniscus disappears, indicating there is no longer a distinction between liquid and gas. The meniscus returns as it is taken back below the critical point.

The second movie shows what effect supercritical CO2 has on PLGA (a polymer approved by the regulatory agencies for drug delivery). As you will see, as the CO2 becomes supercritical, the polymer liquefies.

The next movie shows a short burst of atomisation of a polymer/drug mixture. By careful nozzle selection and control of the atomisation environment, we can control particle formation.

  Reproduced with kind permission from the University of Nottingham.